Editor's Note: This video was filmed on May 7th.
Corcept Therapeutics (CORT -2.26%) shares were slammed last week after a phase 3 trial for mifepristone to treat patients with depression was stopped after an independent data monitoring committee indicated that the drug would probably not provide a statistically significant benefit to currently enrolled patients. The data was from 266 patients in a study that was intended to expand up to 450 patients, but instead of sinking more money into the study by continuing, Corcept's management decided to end the trial and focus on other potential indications.
Indications as diverse as breast cancer, post-traumatic stress disorder, and alcohol dependence.
What to make of this diversity? Does it signify a management that is scattershotting?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give you their answer and their thoughts on the company.
